These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 28375658)
1. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. Jain RK Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658 [TBL] [Abstract][Full Text] [Related]
2. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Aronson R Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379 [TBL] [Abstract][Full Text] [Related]
3. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. Kim ES; Deeks ED Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Rizos CV; Filippatos TD; Elisaf MS Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374 [TBL] [Abstract][Full Text] [Related]
5. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Gallwitz B Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Tan X; Hu J Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910 [TBL] [Abstract][Full Text] [Related]
9. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Lingvay I Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871 [TBL] [Abstract][Full Text] [Related]
10. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Hu J; Zou P; Zhang S; Zhou M; Tan X Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159 [TBL] [Abstract][Full Text] [Related]
11. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156 [TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. DeFronzo RA; Lee C; Kohler S Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153 [TBL] [Abstract][Full Text] [Related]
14. Glyxambi--a new combination for type 2 diabetes. Med Lett Drugs Ther; 2015 Apr; 57(1467):65-6. PubMed ID: 25897551 [No Abstract] [Full Text] [Related]
15. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. Forst T; Falk A; Andersen G; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L Diabetes Obes Metab; 2017 Apr; 19(4):489-495. PubMed ID: 28009472 [TBL] [Abstract][Full Text] [Related]
16. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754 [TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Dey J Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073 [TBL] [Abstract][Full Text] [Related]
19. Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies. Chenchula S; Varthya SB; Padmavathi R Curr Diabetes Rev; 2022; 18(4):e100921196392. PubMed ID: 34514991 [TBL] [Abstract][Full Text] [Related]
20. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Scheen AJ Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]